NEW YORK (GenomeWeb News) – Qiagen said today that it has acquired Germany's ESE, a privately held developer and manufacturer of UV and fluorescence optical measurement devices, for $19 million in cash.

ESE's optical measurement systems are used in medical and industrial applications, and can detect fluorescent signals in a wide range of molecular testing applications, most notably in nucleic acid-based point-of-care testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.